Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedUpdated site revision from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedThe page now displays Revision: v3.4.2, replacing v3.4.1, which is a minor update with no changes to study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedThe recruitment/status changed to Completed. The study completion date (Actual) is listed as 2026-01-09, with updates through 2026-01-30 and a new revision (v3.4.1).SummaryDifference0.4%

- Check47 days agoChange DetectedAdded a Show glossary option and updated page metadata to include 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. Removed/changed older labels such as 'Last Update Submitted that met QC Criteria' (capitalization), 'No FEAR Act data', and the older 'Revision: v3.3.4'.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision: v3.3.4 is now displayed on the page, replacing v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded a Locations section listing Maryland as a study site. Removed the HHS Vulnerability Disclosure link and the older Maryland Locations entry.SummaryDifference0.2%

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.